Barclays
IRLA

Barclays’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Barclays’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$491 Buy
+27
New +$621 ﹤0.01% 5010
2026
Q1 		– Hold
0
– – – 5357
2025
Q4 		– Hold
0
– – – 5152
2025
Q3 		– Hold
0
– – – 5400
2025
Q2 		– Hold
0
– – – 5127
2025
Q1 		– Sell
-1
Closed -$305 – 5157
2024
Q4 		$187 Hold
1
– – ﹤0.01% 5175
2024
Q3 		$78 Hold
1
– – ﹤0.01% 5191
2024
Q2 		$75 Hold
1
– – ﹤0.01% 4762
2024
Q1 		$106 Hold
1
– – ﹤0.01% 5000
2023
Q4 		$105 Hold
1
– – ﹤0.01% 5168
2023
Q3 		$224 Hold
1
– – ﹤0.01% 4532
2023
Q2 		$151 Hold
1
– – ﹤0.01% 4427
2023
Q1 		$156 Buy
+1
New +$196 ﹤0.01% 4987
2022
Q3 		– Sell
-5
Closed -$2K – 5064
2022
Q2 		$2K Sell
5
-17
-77% -$12K ﹤0.01% 4888
2022
Q1 		$26K Sell
22
-108
-83% -$147K ﹤0.01% 4355
2021
Q4 		$329K Buy
130
+89
+217% +$543K ﹤0.01% 3379
2021
Q3 		$756K Buy
41
+27
+193% +$429K ﹤0.01% 2952
2021
Q2 		$143K Sell
14
-53
-79% -$444K ﹤0.01% 3698
2021
Q1 		$480K Buy
67
+40
+148% +$288K ﹤0.01% 3200
2020
Q4 		$149K Sell
27
-9
-25% -$79.7K ﹤0.01% 3940
2020
Q3 		$360K Sell
36
-7
-16% -$63.7K ﹤0.01% 3466
2020
Q2 		$400K Buy
43
+24
+126% +$220K ﹤0.01% 3526
2020
Q1 		$175K Sell
19
-42
-69% -$415K ﹤0.01% 4407
2019
Q4 		$680K Buy
61
+53
+663% +$320K ﹤0.01% 4024
2019
Q3 		$39K Sell
8
-22
-73% -$135K ﹤0.01% 6009
2019
Q2 		$253K Buy
+30
New +$179K ﹤0.01% 4900

Other funds holding IRLA

Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays's IRLA Position: Q2 2026 in Review

Barclays opened a new position in IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026: 27 shares worth $491. The stake represents ﹤0.01% of the portfolio and ranks #5010 among its holdings. This is a return to the name: Barclays previously reported a position in IRLA as recently as Q4 2024.

Barclays first reported a position in IRLA in Q2 2019 and has held it in 22 quarters since. The position peaked at $756K in Q3 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Barclays held 27 shares of IRulya Therapeutics Inc. Common Stock worth $491 as of Q2 2026.
  • IRulya Therapeutics Inc. Common Stock was a new Barclays position in Q2 2026.
  • IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5010 holding.
  • Barclays first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and has held it in 22 quarters since.
  • Barclays's IRulya Therapeutics Inc. Common Stock position peaked at $756K in Q3 2021.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.